Family owned
Did you know that Boehringer is still family-owned? Read this article to learn more about our culture. Check out our Careers Page for more talent insights!
Search
Animal Health
Companion Animals, Horse Pets and Equines
Management Rotation | Academic Programs
Management Rotation Program
What we do
Boehringer Ingelheim is a multinational corporation with divisions dedicated to Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
Medicine & Regulatory Affairs
Medicine & Regulatory Affairs
Pushing for Progress
Pushing for Progress
First half 2019: High levels of investment in R&D and robust organic growth
First half 2019: High levels of investment in R&D and robust organic growth
Digital Health
Find out how Boehringer Ingelheim are helping to shape the change in digital health through the use of digital tools and technologies.
Who are we?
Started in 1885 by Albert Boehringer, this independent family-owned company has grown into a top contributor in Human Pharma and Animal Health.
Anna Race
Human Pharma Sales Director for UK & Ireland, Anna Race discusses how she enjoys making a difference within the company.
Innovation in Immunology | Human Health | Boehringer Ingelheim US
BI's Immunology & Respiratory research combines our ability to address unmet medical needs with pioneering patient-centered approaches.
Contact Our Team | Human Health | Boehringer Ingelheim US
Find all our contact information here as well as the latest updates on where you can meet our partnering teams virtually or in person.
Boehringer Ingelheim acquires Abexxa Biologics to further expand its research efforts in cancer immunology and novel immunotherapeutic approaches
Boehringer Ingelheim acquires Abexxa Biologics to further expand its research efforts in cancer immunology and novel immunotherapeutic approaches
Andreas Lenk
Andreas Lenk, Head of Legal and Compliance Germany, discusses his role supporting human pharma and animal health business in legal and compliance matters.
Top-line Phase II Data for treatment of MASH
Boehringer Ingelheim and Zealand Pharma announced top-line Phase II data for treatment of metabolic dysfuntion-associated steatohepatitis (MASH).
Digital solutions save lives
Digital solutions save lives
Work life balance
It is important that employees have a balance between professional and personal lives, so we offer various leave options and flexible working schedules.
Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer
Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer
Bigger Role in Ensuring Food Security | Boehringer Ingelheim US
As the population of the earth grows, animal health becomes fundamental in ensuring well-being and the global protein supply. Click here to find out more.
Boehringer Ingelheim Office Hours
Boehringer Ingelheim Office Hours
Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases
Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases
Building lasting partnerships for a better future
Working with the University of Georgia, we’ve co-created a sustainability training initiative that benefits people, animals and the planet.
Our Mission
Our Story
Animal Health: Our Responsibility
BI's commitment to animal health is reflected in our more than 100 years of successful company history. It is also at the core of sustainability.
Animal Health Innovation
Animal Health Innovation